Clinical trial
Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
NCT04914247 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Individual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
- Lead sponsor
- Actelion
- Phase
- Expanded access
- Overall status
- Approved for marketing
- Start date
- Not reported
- Completion date
- Not reported
- Enrollment
- Not reported
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
non-healing wound, thromboangiitis obliterans